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Knowing the human immunodeficiency virus (HIV) serostatus of
patients at the time of cancer diagnosis or cancer recurrence is pre-
requisite to coordinating HIV and cancer treatments and improv-
ing treatment outcomes. However,  there are no published data
about HIV testing among cancer survivors in the United States.
We sought to provide estimates of the proportion of cancer surviv-
ors tested for HIV and to characterize factors associated with hav-
ing had HIV testing.
Methods
We used data from the 2009 Behavioral Risk Factor Surveillance
System to calculate the proportion of cancer survivors under age
65 who had undergone HIV testing, by demographic and health-
related factors and by state. Adjusted proportion estimates were
calculated by multivariable logistic regression.
Results
Only 41% of cancer survivors in the United States under the age
of 65 reported ever having had an HIV test. The highest propor-
tion of survivors tested was among patients aged 25 to 34 years
(72.2%), non-Hispanic blacks (59.5%), and cervical cancer surviv-
ors (51.2%). The proportion tested was highest in the District of
Columbia (68.3%) and lowest in Nebraska (24.1%). Multivariable
analysis showed that factors associated with HIV testing included
being non-Hispanic  black or  Hispanic,  being younger,  having
higher education, not being married or living with a partner, not
being disabled,  and having medical  cost  concerns.  Having an
AIDS-related cancer was associated with HIV testing only among
females.
Conclusion
The proportions of  HIV testing varied substantially  by demo-
graphic and health-related factors and by state. Our study points to
the need for public health interventions to promote HIV testing
among cancer survivors.
Introduction
In 2010, about 50,000 new human immunodeficiency virus (HIV)
infections occurred in the United States, and more than 1.1 mil-
lion people were living with HIV infection (1,2). About 16% of
HIV infections go undetected (2). Since 2006, the Centers for Dis-
ease Control and Prevention (CDC) has recommended HIV test-
ing as a routine part of medical care for all persons aged 13 to 64
years (3). Compared with the general population, people with HIV
infection  have  increased  cancer  risks;  Kaposi  sarcoma,  non-
Hodgkin lymphoma, and cervical cancer are AIDS-related can-
cers (4,5). Because of co-infections with hepatitis B and C and Ep-
stein-Barr virus, HIV-infected people also have elevated risks for
non-AIDS–related cancers, such as liver cancer and Hodgkin dis-
ease (6).
Driven by improvements in early detection and treatment, cancer
survival rates have increased substantially in the past 30 years (7).
By 2007, nearly 12 million US cancer survivors were living, and
the number is projected to reach about 18 million by 2022 (8,9).
Given the high prevalence of both cancer and HIV infection and
the natural linkage between the two, occurrence of HIV infection
in cancer survivors is not rare. Patel et al reported that for HIV-in-
fected persons, having AIDS-related cancers, a lower cluster of
differentiation (CD4) cell count, and high viral load at cancer dia-
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gnosis were positively associated with poor 5-year survival (10).
Undiagnosed HIV infection among cancer patients may contrib-
ute to poor cancer treatment outcomes and delay timely HIV care
and treatment, resulting in increased risks for death (11). Identific-
ation of cancer survivors who have never been tested for HIV in-
fection can reduce that risk.
To our knowledge, little is known about HIV testing among can-
cer survivors (11). This study’s objective was to describe the pro-
portion of cancer survivors tested for HIV by demographic and
health-related variables, to provide state-specific estimates of HIV
testing, and to characterize factors associated with HIV testing.
Methods
Data source
Data for this analysis came from the 2009 Behavioral Risk Factor
Surveillance System (BRFSS), an ongoing, state-based, random-
digit–dialed telephone survey of the noninstitutionalized US civil-
ian population aged over 18 years. The BRFSS (www.cdc.gov/
BRFSS/) collects information on diseases, health-related behavi-
ors, preventive health practices, and access to health care in the
United States. In 2009, BRFSS was conducted in all 50 states, the
District  of Columbia,  Puerto Rico,  the US Virgin Islands,  and
Guam. The median response rate for the 2009 BRFSS was 52.5%,
and the median cooperation rate was 75% (12).
Study subjects and variables
In accordance with CDC’s recommended HIV testing criteria (3),
we restricted our analysis to persons who reported a history of
cancer, were aged 18 to 64 years, and fell within the age range of
the BRFSS survey.
Cancer-related variables
Respondents were asked whether they had ever been told by a
doctor, nurse, or other health care professional that they had can-
cer. Respondents who answered yes were asked how many differ-
ent types of cancer they had had, the age at which they were first
told that they had cancer, and for respondents who reported hav-
ing had more than one type of cancer, which type of cancer had
most  recently  been  diagnosed.  Respondents  who were  unsure
about their history of cancer or who refused to answer the ques-
tion were excluded from the analysis.
For cancer survivors, the duration of cancer survivorship was cal-
culated by using the respondent’s current age and the age at first
cancer diagnosis. Cancer types were grouped as AIDS-related can-
cers (non-Hodgkin lymphoma and cervical cancer) and non-AIDS-
related  cancers  (ie,  prostate,  female  breast,  colon,  and  liver;
melanoma and other skin cancers; and other non-AIDS–related
cancers) (5). Information on Kaposi sarcoma was not available
from the BRFSS questionnaires, so we were unable to include it
among AIDS-related cancers.
HIV-related variables
Respondents were also asked whether they had ever been tested
for HIV. Persons were considered to have recent HIV risk behavi-
ors if they answered yes to any of the following questions regard-
ing the past year: 1) Have you used intravenous drugs? 2) Have
you been treated for a sexually transmitted disease? 3) Have you
given or received money or drugs in exchange for sex? and 4)
Have you had anal sex without a condom?
Other variables
We examined the following factors, which were potentially re-
lated to HIV testing: demographics (sex, race/ethnicity, age at in-
terview, education, and marital status), psychological status (emo-
tional support and life satisfaction), health care access (insurance
status, being concerned about medical costs in the past 12 months,
and having a routine checkup in the past 12 months), and disabil-
ity status, which was defined as being limited in any way in any
activities because of physical, mental, or emotional problems.
Statistical analyses
We examined HIV testing among cancer survivors by stratifying
by the aforementioned variables. Proportions tested for HIV were
age-standardized to the age distribution of cancer survivors in the
2009 BRFSS. Ninety-five percent confidence intervals around the
estimated proportions were calculated on the basis of a logit trans-
formation. Statistical testing for differences in age-standardized
measures was performed using general linear contrasts. We also
calculated estimated proportions tested for each of the 50 states
and the District of Columbia. A multivariable logistic regression
model was fitted to determine the adjusted relationships between
HIV testing and the aforementioned demographic and health-re-
lated variables among cancer survivors in the United States. Age
and time since cancer diagnosis were treated as continuous vari-
ables in the model and transformed by using restricted cubic spline
functions  to  allow for  nonlinearity.  The adjusted  associations
between discrete variables and HIV testing are presented as pre-
dictive margins. The predictive margin for a specific group repres-
ents the average predicted response if everyone in the sample had
been in that group. Because AIDS-related cancer types vary for
men and women, we included a term describing sex by AIDS-re-
lated cancer interaction in the model to assess whether the effect
varied by sex. Statistical testing for the age-adjusted and multivari-
able analyses was based on the Wald F test. We performed the
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analysis by using SAS version 9.3 (SAS Institute Inc) with SU-
DAAN version 11.0.0 (RTI International) along with the RMS
version 3.6–3 and survey packages version 3.28–2, components of
R version 3.0.1 (R Foundation for Statistical Computing) to ac-
count for the complex sampling design and to allow for weighted
estimates. Significance was set at P < .05.
Results
Of 407,402 persons interviewed during 2009 who answered the
questions about cancer history, 59,173 reported a history of can-
cer. Of these, 24,485 were aged 18 to 64 years and were included
in our analysis. Most cancer survivors were women (62.3%), non-
Hispanic white (83.5%), aged 45 to 64 years (74.6%), and had
health insurance (89.5%).  About 13% of cancer survivors had
AIDS-related cancers: 11.5% had cervical cancer and 1.9% non-
Hodgkin lymphoma. Approximately 3% of cancer survivors repor-
ted at least 1 HIV risk behavior in the past year.
Of cancer survivors aged 18 to 64 years, 40.8% reported having
ever had an HIV test (Table 1). The proportion who reported HIV
testing varied significantly by race/ethnicity, age, education, can-
cer type,  time since cancer diagnosis,  and HIV risk behaviors.
Within these respective categories, those most likely to have been
tested included non-Hispanic blacks (59.5%), patients aged 25 to
34 years (72.2%), patients with less than a high school education
(45.0%), cervical cancer survivors (51.2%), survivors 5 to 9 years
post cancer diagnosis (42.9%), and those who reported engaging
in at least 1 HIV risk behavior in the past year (58.0%). Measures
of emotional support, life satisfaction, employment status, marital
status, disability status, health insurance, and medical cost con-
cern also were significantly associated with HIV testing. History
of HIV testing varied significantly by state, ranging from 68.3% in
the District of Columbia to 24.1% in Nebraska (Table 2). Among
all states, the District of Columbia (68.3), Maryland (50.6%) and
California (48.7%) had the highest proportions of cancer surviv-
ors who reported having been tested for HIV.
The multivariable logistic regression analysis (Table 3) revealed
that women with an AIDS-related cancer, persons who had ever
had a disability, and patients with medical cost concern were more
likely to report having had an HIV test than men with cancer and
women with non-AIDS–related  cancer, those who did not have a
disability or those who did not have medical cost concerns. Other
significant findings included higher prevalences of testing among
non-Hispanic blacks and Hispanics, patients with at least some
college education, and patients who were not currently married or
living with a partner. After adjusting for all variables, health insur-
ance, emotional support, life satisfaction, employment status, and
HIV risk behaviors were no longer significantly associated with
HIV testing. There was a significant nonlinear association between
age and HIV testing. Increasing age was significantly associated
with a decline in HIV testing above age 35 (Figure 1). HIV test-
ing prevalence tended to be slightly higher with increasing time
since diagnosis up to around 10 years with slightly lower testing
with increasing years since diagnosis beyond 20 years (Figure 2).
However, this relationship was not significant (P = .07).
Figure  1.  Model-adjusted  relationship  between  age  and  human
immunodeficiency virus (HIV) testing among cancer survivors aged 18 to 64
years,  United  States,  2009,  Behavioral  Risk  Factor  Surveillance  System.
Abbreviation: CI, confidence interval.
 
Figure  2.  Model-adjusted  relationship  between  age  and  human
immunodeficiency virus (HIV) testing among cancer survivors aged 18 to 64
years,  United  States,  2009,  Behavioral  Risk  Factor  Surveillance  System.
Abbreviation: CI, confidence interval.
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Discussion
Our study, based on the largest telephone survey of adults in the
United States, found that only 41% of US cancer survivors under
age 65 in 2009 had ever had an HIV test. The likelihood of having
had HIV testing varied markedly by state. Factors associated with
HIV  testing  included  being  non-Hispanic  black  or  Hispanic,
younger age, having higher education, not being married or living
with a partner, being disabled, and having medical cost concerns.
Having an AIDS-related cancer was associated with HIV testing
only among women.
Although information on the proportion tested for HIV is lacking
for cancer survivors, it has been widely reported for the US gener-
al population. In 2013, CDC reported, on the basis of the National
Health Interview Survey (NHIS), that the percentage of adults
who had ever been tested for HIV significantly increased from
36.6% in 2000 to 45.0% in 2010 (13). Similar to what we have ob-
served  among  cancer  survivors,  NHIS  analyses  showed  that
among the general population, non-Hispanic blacks, people aged
25 to 34 years, and people with a reported risk for HIV infection
had the highest proportion of HIV testing (13). A British study ex-
amined HIV testing among cancer patients in a clinic where HIV
testing was recommended for all lymphoma patients (14). This
study reported that only 59% of 113 lymphoma patients under-
went an HIV test after their cancer diagnosis, and a high preval-
ence of HIV co-infection (8.0%) was observed (14). In 2013, the
US Preventive Services Task Force also recommended that clini-
cians screen adolescents and adults aged 15 to 65 years who were
at average risk for HIV infection (15). The low percentage of HIV
testing reported by our study emphasizes the need for more efforts
to promote HIV testing among cancer survivors. Our study may
serve as a baseline measure to monitor changes in HIV testing
among cancer survivors.
Compared with the overall  population,  adolescents  and young
adults are disproportionately affected by HIV (3). This finding
may partially account for the decline in HIV testing with age, as
suggested by our study. However, among persons living with a
diagnosed HIV infection, the percentage aged 50 years or older in-
creased from 28.6% in 2007 to 32.7% in 2009 (1). One possible
explanation is that HIV testing increased over time among this
older population (13). The positive associations between HIV test-
ing and disabilities as identified in our study were consistent with
a 2002 NHIS study among the general population (16). That study
revealed that adults with physical and mental disability were more
likely to report having had an HIV test than nondisabled adults
(16). One explanation for the greater likelihood of HIV testing
among  physically  and  mentally  disabled  adults  was  their  in-
creased risk of rape and sexual abuse and a higher rate of particip-
ation in HIV risk behaviors (16).
Our study shows that about 60% of US cancer survivors under age
65 have never had an HIV test. Although non-Hodgkin lymphoma
and cervical cancers are AIDS-related cancers, almost half of pa-
tients  with  these  cancers  had  never  been  tested  for  HIV.  The
nontargeted “opt-out” HIV testing (the test will be performed un-
less the patient declines) in all health care settings, recommended
by CDC in 2006, has not been widely implemented (11).  This
may, in part, contribute to the low reports of HIV testing among
cancer survivors. Other contributing factors have not been repor-
ted in the literature. However, studies have shown that for the gen-
eral population, fear, stigma, and discrimination associated with an
HIV diagnosis; physicians’ attitudes; and the need for additional
health care personnel and effort affect adoption of HIV testing
(13,17,18). In addition, the cost or reimbursement of the cost for
HIV testing are shared concerns of both patients and health care
providers (19). In our study, we found that only 16.7% of cancer
survivors reported having medical cost concerns, and cancer sur-
vivors who had medical cost concerns were more likely to have
had an HIV test than cancer survivors who had no such concerns.
In 2009, the Centers for Medicare and Medicaid Services allowed
reimbursement for routine HIV testing (20). However, the changes
in Medicare and Medicaid coverage may not have had a substan-
tial effect on HIV testing in our study population because of the
age limits of 18 to 64 years and the time the survey was conduc-
ted. One possible explanation is that medical cost concerns are a
surrogate for having low income. Those who have low income
may be perceived to be at higher risk for HIV by health care pro-
viders and, therefore, may be more likely to be tested. Additional
research is warranted to further investigate this issue.
Separate  written  consent  for  HIV testing  among nonpregnant
adults is another well recognized barrier. Twenty states had laws
or regulations that required separate written consent when CDC
released its 2006 HIV testing recommendation (17). By 2008, 11
states, including California and Maryland, enacted new legislation
or regulations to remove this barrier (17). Our findings that in
2009, the District of Columbia, Maryland, and California had the
highest reports of HIV testing among all the states may be par-
tially due to the absence of requirements for separate consent in
these states. Removal of requirements for a separate written con-
sent for HIV testing in every state would likely promote HIV test-
ing and reduce variations among states.
Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer oc-
cur in excess in persons living with HIV (5). These cancers have
been deemed AIDS-related conditions (5). Previous studies also
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indicate that HIV-infected persons are at higher risk than the gen-
eral population for several non-AIDS–related cancers, such as anal
cancer, Hodgkin disease, liver cancer, lung cancer, melanoma, and
colorectal cancer (21,22). Besides the advent of highly active anti-
retroviral therapy, which has prolonged survival of HIV-infected
patients, other factors that may account for increased cancer risk
are immunosuppression (23,24), co-infection with an oncogenic
virus (25–27),  and unhealthy behaviors  such as  smoking (28).
Awareness of HIV status is important at the time of cancer dia-
gnosis or cancer recurrence to avoid treatment-related complica-
tions from co-infection with HIV, drug interactions, potential ef-
fects of chemotherapy on the CD4 cell count, and HIV viral load
(14). Early identification of patients with HIV infection would al-
low early implementation of HIV infection prevention and control
measures to reduce hospital-acquired infections among patients
and health care providers (29,30). Coordination of anticancer and
anti-HIV therapies  could  improve  treatment  outcomes  among
HIV-infected adults newly diagnosed with cancer or with cancer
recurrence. Additionally, by knowing patients’ HIV status, health
care providers can identify cancer survivors who are at elevated
risk for a secondary cancer and educate them about the need for
cancer screenings.
Our study has several limitations. First, BRFSS data were self-re-
ported and subject to recall bias. Recall bias may be responsible
for the slightly higher prevalence of certain cancers when com-
pared with a study that used cancer registry data (8). HIV testing
history data were self-reported and may be subject to social de-
sirability or recall biases. Opt-out testing may also contribute to
recall biases. For instance, patients may not have explicitly con-
sented, so they may have been unaware when they were tested.
Because of the limitations of recall bias and self-report, this study
may seriously underestimate actual HIV testing among cancer sur-
vivors. Second, we are not able to determine whether the testing
occurred before, at  the time of,  or after their cancer diagnosis.
Third, because the 2009 BRFSS sampled only respondents with a
landline telephone, persons without a landline telephone were ex-
cluded from this study. Fourth, BRFSS is limited to noninstitution-
alized US citizens; cancer survivors who lived in nursing homes,
long-term care facilities, or hospice were excluded. Last, the low
response rate of 52.2% in the 2009 survey may limit the generaliz-
ability of the results to all cancer survivors living in the United
States.
In conclusion, in 2009 about 60% of US cancer survivors under
age 65 had never had an HIV test. The proportion of HIV testing
varied substantially by demographic and health-related factors and
by state.  Increasing the proportion of new HIV infections dia-
gnosed before  progression to  AIDS is  a  Healthy People  2020
(www.healthypeople.gov/2020/topicsobjectives2020/default) ob-
jective. One of the targets in the National HIV/AIDS Strategy is to
increase the percentage of people who are living with HIV and
know their serostatus from 79% to 90% by 2015. (13) Knowing
the HIV serostatus at the time of cancer diagnosis or cancer recur-
rence is prerequisite to coordinating HIV and cancer treatments
and improving treatment outcomes. Thus, our study points to the
need for public health interventions to promote HIV testing among
cancer survivors, especially among the demographic subgroups
and states with a low proportion of HIV testing. With HIV testing,
health care providers also can identify cancer survivors who are at
elevated risk for a secondary cancer and educate them about the
need for cancer screenings.
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Tables
Table 1. Age-Standardizeda Proportion of US Cancer Survivors Aged 18 to 64 Yearsb  Tested for HIV, Behavioral Risk Factor Surveil-
lance System, 2009
Characteristics Nc % (95% CI) P Value
Total 23,626 40.8 (39.7–42.0) NA
Sex
Male 7,180 41.6 (39.4–43.8) .21
Female 16,446 40.0 (38.7–41.3)
Race/ethnicity
Non-Hispanic white 20,605 37.7 (36.6–38.9)
.001
Non-Hispanic black 1,207 59.5 (54.7–64.1)
Hispanic 839 52.3 (46.9–57.7)
Non-Hispanic other 764 48.3 (40.6–56.1)
Age, y
18–24 148 52.4 (39.6–64.8)
<.001
25–34 874 72.2 (66.7–77.1)
35–44 2,535 59.1 (55.7–62.4)
45–54 6,979 42.9 (40.8–45.0)
55–64 13,090 26.2 (24.9–27.6)
Education
<High school graduate 1,382 45.0 (40.6–49.4)
<.001
High school graduate 5,879 35.8 (33.6–38.0)
Some college 6,971 43.9 (41.7–46.2)
College graduate 9,374 40.8 (39.0–42.6)
Employment
Employed 13,696 38.4 (37.0–39.9)
<.001
Not employed 9,886 44.9 (43.1–46.7)
Marital status
Married or living with a partner 14,858 36.4 (35.1–37.8)
<.001Divorced, separated, or widowed 6,547 53.6 (51.3–55.8)
Never married 2,150 54.7 (50.8–58.5)
Type of cancer
AIDS-related cancer
Cervical cancer 2,600 51.2 (47.9–54.5)
<.001
Non-Hodgkin lymphoma 284 44.8 (34.7–55.4)
Abbreviation: HIV, human immunodeficiency virus; CI, confidence interval; NA, not applicable.
a Results for all variables except age were age-standardized to the age distribution of cancer survivors in the 2009 BRFSS.
b 612 participants were excluded because of missing HIV status.
c Numbers may not add up to totals because of “don't know,” “refused,” or missing responses.
(continued on next page)
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(continued)
Table 1. Age-Standardizeda Proportion of US Cancer Survivors Aged 18 to 64 Yearsb  Tested for HIV, Behavioral Risk Factor Surveil-
lance System, 2009
Characteristics Nc % (95% CI) P Value
Non-AIDS–related cancer
Prostate 1,073 47.3 (42.7–51.9)
<.001
Female breast 3,771 37.3 (34.6–40.1)
Colon 832 36.6 (30.7–42.9)
Melanoma 2,407 35.0 (31.8–38.5)
Other skin 5,357 36.7 (34.5–39.0)
Liver 83 61.9 (48.3–73.9)
Other 6,549 42.7 (40.5–44.9)
Time since cancer diagnosis, y
0–4 8,000 38.7 (36.8–40.6)
.04
5–9 5,084 42.9 (40.4–45.4)
10–19 5,537 41.5 (39.3–43.8)
≥20 4,473 39.7 (36.3–43.1)
Emotional support
Always 18,369 39.1 (37.8–40.4)
<.001Sometimes 3,197 47.3 (44.2–50.4)
Rare or none 1,909 47.0 (43.3–50.8)
Life satisfaction
Very satisfied 10,125 36.9 (35.2–38.6)
<.001
Satisfied 11,339 42.0 (40.4–43.7)
Dissatisfied 1,531 52.1 (48.1–56.0)
Very dissatisfied 479 53.1 (46.2–59.8)
Health insurance
Yes 21,239 40.4 (39.2–41.7)
.03
No 2,363 44.4 (41.1–47.7)
Time since last checkup
Within past year 17,848 41.3 (39.9–42.6)
.24
1 – <2 y 2,681 38.7 (35.6–41.9)
2 – <5 y 1,421 40.8 (36.7–45.1)
≥5 y 1,320 37.9 (33.8–42.2)
Never 166 48.5 (36.8–60.3)
Medical cost concern
Abbreviation: HIV, human immunodeficiency virus; CI, confidence interval; NA, not applicable.
a Results for all variables except age were age-standardized to the age distribution of cancer survivors in the 2009 BRFSS.
b 612 participants were excluded because of missing HIV status.
c Numbers may not add up to totals because of “don't know,” “refused,” or missing responses.
(continued on next page)
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(continued)
Table 1. Age-Standardizeda Proportion of US Cancer Survivors Aged 18 to 64 Yearsb  Tested for HIV, Behavioral Risk Factor Surveil-
lance System, 2009
Characteristics Nc % (95% CI) P Value
Yes 3,713 48.5 (45.8–51.2)
<.001
No 19,875 39.2 (37.9–40.5)
Ever had disability
Yes 8,225 49.9 (48.0–51.9)
<.001
No 15,306 36.4 (35.1–37.8)
HIV risk behaviors
Yes 520 58.0 (51.0–64.7)
<.001
No 23,069 40.5 (39.3–41.7)
Abbreviation: HIV, human immunodeficiency virus; CI, confidence interval; NA, not applicable.
a Results for all variables except age were age-standardized to the age distribution of cancer survivors in the 2009 BRFSS.
b 612 participants were excluded because of missing HIV status.
c Numbers may not add up to totals because of “don't know,” “refused,” or missing responses.
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Table 2. Age-Standardizeda Proportion of HIV Tests Among Cancer Survivors Aged 18 to 64 Years, by State, Behavioral Risk Factor
Surveillance System, 2009
State N % (95% CI)
Total 23,626 40.8 (39.7–42.0)
Alabama 382 44.6 (37.9–51.4)
Alaska 131 45.1 (35.3–55.4)
Arizona 327 38.8 (31.2–46.9)
Arkansas 210 37.4 (30.4–44.9)
California 794 48.7 (44.6–52.8)
Colorado 679 42.1 (37.5–46.7)
Connecticut 322 38.3 (32.2–44.8)
Delaware 240 44.7 (37.9–51.7)
District of Columbia 189 68.3 (61.3–74.6)
Florida 762 46.5 (41.3–51.6)
Georgia 342 40.5 (34.7–46.5)
Hawaii 361 36.7 (30.4–43.5)
Idaho 330 30.0 (24.8–35.8)
Illinois 286 34.4 (27.7–41.8)
Indiana 525 39.5 (34.3–45.0)
Iowa 296 30.7 (24.1–38.2)
Kansas 1,064 34.2 (31.1–37.3)
Kentucky 629 36.2 (30.4–42.3)
Louisiana 463 46.4 (40.8–52.0)
Maine 501 38.1 (33.4–43.1)
Maryland 512 50.6 (45.2–56.0)
Massachusetts 896 42.2 (37.8–46.8)
Michigan 479 37.4 (32.0–43.1)
Minnesota 279 35.4 (29.5–41.7)
Mississippi 552 39.8 (35.1–44.6)
Missouri 282 31.1 (24.5–38.6)
Montana 465 41.5 (36.1–47.2)
Nebraska 779 24.1 (19.6–29.2)
Nevada 255 45.6 (36.7–54.7)
New Hampshire 352 37.4 (32.4–42.7)
New Jersey 644 39.2 (34.6–44.0)
New Mexico 502 43.7 (38.5–49.1)
New York 381 40.4 (34.4–46.7)
Abbreviation: HIV, Human immunodeficiency virus; CI, confidence interval.
a Age-standardized to the age distribution of cancer survivors in the Behavioral Risk Factor Surveillance System, 2009.
(continued on next page)
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(continued)
Table 2. Age-Standardizeda Proportion of HIV Tests Among Cancer Survivors Aged 18 to 64 Years, by State, Behavioral Risk Factor
Surveillance System, 2009
State N % (95% CI)
North Carolina 745 45.7 (41.4–50.1)
North Dakota 232 29.6 (23.6–36.4)
Ohio 525 30.0 (25.2–35.3)
Oklahoma 466 38.8 (34.3–43.5)
Oregon 306 40.5 (35.0–46.3)
Pennsylvania 475 34.2 (28.9–39.9)
Rhode Island 362 31.6 (26.2–37.6)
South Carolina 586 37.5 (32.1–43.3)
South Dakota 343 25.1 (19.6–31.4)
Tennessee 284 45.7 (38.6–53.0)
Texas 609 46.7 (40.6–52.8)
Utah 537 29.1 (24.7–33.9)
Vermont 417 39.7 (34.7–45.0)
Virginia 286 47.9 (41.5–54.4)
Washington 1,317 44.3 (41.0–47.7)
West Virginia 271 27.9 (22.8–33.5)
Wisconsin 250 29.2 (22.3–37.2)
Wyoming 404 38.0 (32.7–43.5)
Abbreviation: HIV, Human immunodeficiency virus; CI, confidence interval.
a Age-standardized to the age distribution of cancer survivors in the Behavioral Risk Factor Surveillance System, 2009.
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Table 3. Model-Adjusted Percentage of HIV Testing by Demographic and Health-Related Characteristics Among US Cancer Surviv-
ors Aged 18 to 64 Years, Behavioral Risk Factor Surveillance System, 2009
Characteristics % (95% CI) P Valuea
Sexb NA <.001
Type of cancerb
Male, AIDS-related cancer 34.2 (16.6–57.5)
<.001
Male, Non-AIDS–related cancer 44.4 (42.2–46.6)
Female, AIDS-related cancer 48.8 (45.4–52.1)
Female, Non-AIDS–related  cancer 36.2 (34.6–37.7)
Race/ethnicity
Non-Hispanic white 38.3 (37.0–39.5)
<.001
Non-Hispanic black 55.5 (49.9–60.9)
Hispanic 53.3 (46.6–59.9)
Non-Hispanic other 45.9 (37.7–54.4)
Age, y Nonlinear <.001
Education
<High school graduate 36.9 (32.6–41.4)
<.001
High school graduate 33.3 (31.1–35.7)
Some college 43.1 (40.8–45.3)




Not employed 41.7 (39.7–43.7)
Marital status
Married or living together 37.4 (35.9–38.9)
<.001Divorced, separated, or widowed 50.6 (48.2–53.0)
Never married 46.2 (41.7–50.7)




Rare or none 38.1 (34.0–42.5)
Life satisfaction
Very satisfied 40.0 (38.0–42.0)
.31Satisfied 40.5 (38.8–42.3)
Dissatisfied 44.1 (39.5–48.7)
Abbreviation: HIV, human immunodeficiency virus; CI, confidence interval; NA, not applicable.
a P value was calculated by using the Wald F test.
b Sex by type of cancer interaction term is included in the model (P = .06). P values are calculated from the simultaneous test so that the main effect and interac-
tion coefficients are both equal to zero.
(continued on next page)
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(continued)
Table 3. Model-Adjusted Percentage of HIV Testing by Demographic and Health-Related Characteristics Among US Cancer Surviv-
ors Aged 18 to 64 Years, Behavioral Risk Factor Surveillance System, 2009
Characteristics % (95% CI) P Valuea





Time since last checkup
Within past year 41.4 (40.0–42.8)
.20
1 – <2 y 38.2 (35.0–41.5)
2 – <5 y 39.1 (34.8–43.6)














Abbreviation: HIV, human immunodeficiency virus; CI, confidence interval; NA, not applicable.
a P value was calculated by using the Wald F test.
b Sex by type of cancer interaction term is included in the model (P = .06). P values are calculated from the simultaneous test so that the main effect and interac-
tion coefficients are both equal to zero.
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